The coming of age of tumour immunotherapy
-
Altmetric Citations
Description
Compared with the earlier incidence of acute infectious diseases, the introduction of vaccines has been one of the major public health success achievements. In contrast, vaccine development to control some persisting infections such as HIV remains a major challenge. There are many similarities with this task and that of controlling tumours by immunotherapy. Generating CTL responses by using pulsed dendritic cells has become a popular approach and has led to success with the mouse model. With...[Show more]
dc.contributor.author | Ada, Gordon | |
---|---|---|
dc.date.accessioned | 2015-12-13T23:24:59Z | |
dc.identifier.issn | 0818-9641 | |
dc.identifier.uri | http://hdl.handle.net/1885/92477 | |
dc.description.abstract | Compared with the earlier incidence of acute infectious diseases, the introduction of vaccines has been one of the major public health success achievements. In contrast, vaccine development to control some persisting infections such as HIV remains a major challenge. There are many similarities with this task and that of controlling tumours by immunotherapy. Generating CTL responses by using pulsed dendritic cells has become a popular approach and has led to success with the mouse model. With viral antigens, priming with DNA plasmids and boosting with a chimeric live vector results in high levels of CTL activity, and is worth trying with cancer. A recent review highlights three other difficulties posed by tumours: epitope stability, maiming or killing of CTL by the tumour, and accessibility of the tumour vasculature to immune components. The new ability to label CTL by staining with specific tetrameric peptide/MHC complexes offers the possibility of effectively studying this third aspect. Our increased knowledge of tumour- associated antigens, virai or otherwise, and our growing ability to manipulate the immune system, offers hope that control of at least some human tumours may be within reach. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.source | Immunology and Cell Biology | |
dc.subject | Keywords: tumor antigen; animal experiment; animal model; blood transfusion; cell killing; chimera; complex formation; conference paper; controlled study; cytotoxic t lymphocyte; dendritic cell; immune response; immunotherapy; major histocompatibility complex; mous Chimeric vectors; Cytotoxic T lymphocytes; Dendritic cells; DNA; Immunotherapy; Neoplasia; Tumour antigens; Vaccination | |
dc.title | The coming of age of tumour immunotherapy | |
dc.type | Journal article | |
local.description.notes | Imported from ARIES | |
local.description.refereed | Yes | |
local.identifier.citationvolume | 77 | |
dc.date.issued | 1999 | |
local.identifier.absfor | 110705 - Humoural Immunology and Immunochemistry | |
local.identifier.ariespublication | MigratedxPub23592 | |
local.type.status | Published Version | |
local.contributor.affiliation | Ada, Gordon, College of Medicine, Biology and Environment, ANU | |
local.description.embargo | 2037-12-31 | |
local.bibliographicCitation.startpage | 180 | |
local.bibliographicCitation.lastpage | 185 | |
local.identifier.doi | 10.1046/j.1440-1711.1999.00803.x | |
dc.date.updated | 2015-12-12T09:22:59Z | |
local.identifier.scopusID | 2-s2.0-0032920776 | |
Collections | ANU Research Publications |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Ada_The_coming_of_age_of_tumour_1999.pdf | 56.85 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator